• 1
    Cao Y & Lam L (2003) Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 55, 171197.
  • 2
    Kufer P, Lutterbuse R & Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22, 238244.
  • 3
    Koelemij R, Kuppen PJ, van de Velde CJ, Fleuren GJ, Hagenaars M & Eggermont AM (1999) Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J Immunother 22, 514524.
  • 4
    Segal DM, Weiner GJ & Weiner LM (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11, 558562.
  • 5
    van Spriel AB, van Ojik HH & van De Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21, 391397.
  • 6
    Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS & Whitlow M (1988) Single-chain antigen-binding proteins. Science 242, 423426.
  • 7
    Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85, 58795883.
  • 8
    Holliger P, Prospero T & Winter G (1993) ‘Diabodies’: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90, 64446448.
  • 9
    Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S et al. (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65, 28822889.
  • 10
    Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M & Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 25622568.
  • 11
    Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D & Weiner LM (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279, 5390753914.
  • 12
    Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE & Adams GP (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65, 14711478.
  • 13
    Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS & Wu AM (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44, 19621969.
  • 14
    Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER & Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293, 4156.
  • 15
    Le Gall F, Reusch U, Little M & Kipriyanov SM (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17, 357366.
  • 16
    Peipp M & Valerius T (2002) Bispecific antibodies targeting cancer cells. Biochem Soc Trans 30, 507511.
  • 17
    Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR & de Leij L (1998) Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76, 232239.
  • 18
    Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T & Kumagai I (1998) Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent – application to a human single-chain Fv fragment. J Immunol Methods 219, 119129.
  • 19
    Skerra A & Schmidt TG (2000) Use of the Strep-Tag and streptavidin for detection and purification of recombinant proteins. Methods Enzymol 326, 271304.
  • 20
    Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 40364042.
  • 21
    Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 31, 752761.
  • 22
    Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597603.
  • 23
    Presta L (2003) Antibody engineering for therapeutics. Curr Opin Struct Biol 13, 519525.
  • 24
    Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26, 19.
  • 25
    Marvin JS & Zhu Z (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26, 649658.
  • 26
    Carter P (2001) Bispecific human IgG by design. J Immunol Methods 248, 715.
  • 27
    Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2007) Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282, 2765927665.
  • 28
    Perisic O, Webb PA, Holliger P, Winter G & Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 12171226.
  • 29
    Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K & Kumagai I (2002) Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem 132, 903909.
  • 30
    Alt M, Muller R & Kontermann RE (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 454, 9094.
  • 31
    Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ & Raubitschek AA (2001) Multimerization of a chimeric anti-CD20 single-chain Fv–Fc fusion protein is mediated through variable domain exchange. Protein Eng 14, 10251033.
  • 32
    Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJ, Baranowska-Kortylewicz J & Batra SK (2000) Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. J Biochem 127, 829836.
  • 33
    Brusselbach S, Korn T, Volkel T, Muller R & Kontermann RE (1999) Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Target 4, 115123.
  • 34
    Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, Von der Lieth CW & Little M (2003) Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 330, 99111.
  • 35
    Korn T, Nettelbeck DM, Volkel T, Muller R & Kontermann RE (2004) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6, 642651.
  • 36
    Arakawa F, Kuroki M, Kuwahara M, Senba T, Ozaki H, Matsuoka Y, Misumi Y, Kanda H & Watanabe T (1996) Cloning and sequencing of the VH and VK genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem 120, 657662.
  • 37
    Umetsu M, Tsumoto K, Hara M, Ashish K, Goda S, Adschiri T & Kumagai I (2003) How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J Biol Chem 278, 89798987.
  • 38
    Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K et al. (2004) A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 53, 497509.
  • 39
    Asano R, Kudo T, Makabe K, Tsumoto K & Kumagai I (2002) Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett 528, 7076.